DGEN.US Deltagen Inc
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -2.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2015.
Is DGEN.US undervalued?
Graham numberThe Graham number of Deltagen Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Deltagen Inc fundamental analysis
No fundamental analysis for Deltagen Inc yet.
Deltagen Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Deltagen Inc
Deltagen Inc. provides drug discovery tools and services to the biopharmaceutical industry. The company offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models, as well as small-molecule and secreted protein drug targets. It also provides target validation data in the areas of immunology and metabolic diseases. The company was incorporated in 1997 and is headquartered in San Mateo, California.
Full company profileDeltagen Inc financial statements
Deltagen Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2012 | 2013 | 2014 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 6.70M | 9.78M | 3.41M | 2.93M | 1.36M | 1.99M | 1.05M | 1.02M | 263K | 770K |
| Gross Profit | 6.70M | 9.78M | - | - | - | - | 711K | 660K | 77.0K | 766K |
| Operating Income | 461K | 3.96M | -253K | 69.0K | -703K | -694K | -53.0K | 112K | 77.0K | -46.0K |
| EBITDA | -461K | 4.00M | -73.0K | 172K | -670K | -673K | -990K | -4.42M | 77.0K | - |
| Net Income | -152K | 4.37M | -95.0K | 37.0K | -687K | -685K | -1.17M | -4.42M | 76.0K | -46.0K |
| EPS | 0.00 | 0.11 | - | - | - | - | - | - | - | - |
| Balance Sheet | ||||||||||
| Total Assets | 15.7M | 9.67M | 7.53M | 7.19M | 7.76M | 7.15M | 6.45M | 2.04M | 1.84M | 1.80M |
| Total Liabilities | 6.04M | 840K | 865K | 566K | 254K | 322K | 401K | 444K | 124K | 129K |
| Shareholders' Equity | 9.70M | 8.83M | 6.66M | 6.63M | 7.51M | 6.83M | 6.05M | 1.60M | 1.72M | 1.67M |
| Cash & Short-term Investments | 11.6M | 6.14M | 3.07M | 5.09M | 5.70M | 3.53M | 95.0K | 85.0K | 23.0K | 47.0K |
| Total Debt | - | - | - | - | - | - | 100K | - | 25.0K | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | - | 2.07M | -1.02M | - | -667K | -2.18M | -665K | 90.0K | -22.0K | 24.0K |
| Capital Expenditure | - | 70.0K | 0.00 | - | 0.00 | 0.00 | 0.00 | 90.0K | 0.00 | 0.00 |
| Free Cash Flow | - | 2.00M | -1.02M | - | -667K | -2.18M | -665K | - | - | - |
| Ratios | ||||||||||
| ROE | -1.6% | 49.5% | -1.4% | 0.6% | -9.2% | -10.0% | -19.2% | -276.1% | 4.4% | -2.8% |
| ROA | -1.0% | 45.2% | -1.3% | 0.5% | -8.9% | -9.6% | -18.1% | -216.1% | 4.1% | -2.6% |
| Net Profit Margin | -2.3% | 44.7% | -2.8% | 1.3% | -50.6% | -34.5% | -110.5% | -432.3% | 28.9% | -6.0% |
| Debt to Equity | - | - | - | - | - | - | 0.02x | - | 0.01x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Deltagen Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 17, 2007
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2015 | - | - | - |
| 2014 | - | - | - |
| 2013 | - | - | - |
| 2012 | - | - | - |
| 2010 | - | - | - |
| 2009 | - | - | - |
| 2007 | USD 2.21M | - | - |
| 2006 | USD 7.72M | 0.20 | 176.7% |
| 2002 | - | - | - |
| 2001 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Deltagen Inc
Ownership data of Deltagen Inc is not available yet.
Deltagen Inc company profile
- Company name
- Deltagen Inc
- Ticker
- DGEN.US
- Exchange
- USA Stocks
- Listed since
- Aug 3, 2000
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 1900 South Norfolk Street, San Mateo, CA, United States, 94403
- Phone
- 650-345-7601
- Website
- deltagen.com
About Deltagen Inc
Deltagen Inc. provides drug discovery tools and services to the biopharmaceutical industry. The company offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models, as well as small-molecule and secreted protein drug targets. It also provides target validation data in the areas of immunology and metabolic diseases. The company was incorporated in 1997 and is headquartered in San Mateo, California.
Deltagen Inc management
2- Dr. Robert J. Driscoll J.D., Ph.D.CEO, President, Secretary & Director · born 1966
- Mr. Daniel RattoChief Financial Officer · born 1958